Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Saved in:
Bibliographic Details
Title: Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
Authors: Burger JA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Barr PM; Department of Medicine, Hematology, and Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Robak T; Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland., Owen C; Division of Hematology and Hematological Malignancies, Tom Baker Cancer Centre, University of Calgary, Calgary, Canada., Tedeschi A; Department of Hematology, Niguarda Ca' Granda Hospital, Milan, Italy., Sarma A; Department of Haematology, St. James's University Hospital, Leeds, United Kingdom., Patten PEM; Department of Haematology, Comprehensive Cancer Centre, King's College London, London, United Kingdom.; Department of Haematology, King's College Hospital, London, United Kingdom., Grosicki S; Department of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland., McCarthy H; Department of Haematological Medicine, Royal Bournemouth General Hospital, Bournemouth, United Kingdom., Offner F; Department of Haematology, Universitair Ziekenhuis Gent, Gent, Belgium., Szafer-Glusman E; Precision Medicine Oncology, AbbVie, North Chicago, IL., Zhou C; Translational Medicine, AbbVie, North Chicago, IL., Szoke A; Clinical Development Oncology, AbbVie, North Chicago, IL., Neumayr L; Clinical Development Oncology, AbbVie, North Chicago, IL., Dean JP; Clinical Development Oncology, AbbVie, North Chicago, IL., Ghia P; Department of Medical Oncology, Medical School, Università Vita-Salute San Raffaele, Milan, Italy.; Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy., Kipps TJ; Division of Hematology-Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA.
Source: Blood [Blood] 2025 Oct 30; Vol. 146 (18), pp. 2168-2176.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40737596
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Burger+JA%22">Burger JA</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Barr+PM%22">Barr PM</searchLink>; Department of Medicine, Hematology, and Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.<br /><searchLink fieldCode="AU" term="%22Robak+T%22">Robak T</searchLink>; Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.<br /><searchLink fieldCode="AU" term="%22Owen+C%22">Owen C</searchLink>; Division of Hematology and Hematological Malignancies, Tom Baker Cancer Centre, University of Calgary, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Tedeschi+A%22">Tedeschi A</searchLink>; Department of Hematology, Niguarda Ca' Granda Hospital, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Sarma+A%22">Sarma A</searchLink>; Department of Haematology, St. James's University Hospital, Leeds, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Patten+PEM%22">Patten PEM</searchLink>; Department of Haematology, Comprehensive Cancer Centre, King's College London, London, United Kingdom.; Department of Haematology, King's College Hospital, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Grosicki+S%22">Grosicki S</searchLink>; Department of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland.<br /><searchLink fieldCode="AU" term="%22McCarthy+H%22">McCarthy H</searchLink>; Department of Haematological Medicine, Royal Bournemouth General Hospital, Bournemouth, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Offner+F%22">Offner F</searchLink>; Department of Haematology, Universitair Ziekenhuis Gent, Gent, Belgium.<br /><searchLink fieldCode="AU" term="%22Szafer-Glusman+E%22">Szafer-Glusman E</searchLink>; Precision Medicine Oncology, AbbVie, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Zhou+C%22">Zhou C</searchLink>; Translational Medicine, AbbVie, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Szoke+A%22">Szoke A</searchLink>; Clinical Development Oncology, AbbVie, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Neumayr+L%22">Neumayr L</searchLink>; Clinical Development Oncology, AbbVie, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Dean+JP%22">Dean JP</searchLink>; Clinical Development Oncology, AbbVie, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Ghia+P%22">Ghia P</searchLink>; Department of Medical Oncology, Medical School, Università Vita-Salute San Raffaele, Milan, Italy.; Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Kipps+TJ%22">Kipps TJ</searchLink>; Division of Hematology-Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227603509%22">Blood</searchLink> [Blood] 2025 Oct 30; Vol. 146 (18), pp. 2168-2176.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7603509 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1528-0020 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200064971%22">00064971 </searchLink><i>NLM ISO Abbreviation: </i>Blood <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40737596
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/blood.2024028205
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2168
    Titles:
      – TitleFull: Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Burger JA
      – PersonEntity:
          Name:
            NameFull: Barr PM
      – PersonEntity:
          Name:
            NameFull: Robak T
      – PersonEntity:
          Name:
            NameFull: Owen C
      – PersonEntity:
          Name:
            NameFull: Tedeschi A
      – PersonEntity:
          Name:
            NameFull: Sarma A
      – PersonEntity:
          Name:
            NameFull: Patten PEM
      – PersonEntity:
          Name:
            NameFull: Grosicki S
      – PersonEntity:
          Name:
            NameFull: McCarthy H
      – PersonEntity:
          Name:
            NameFull: Offner F
      – PersonEntity:
          Name:
            NameFull: Szafer-Glusman E
      – PersonEntity:
          Name:
            NameFull: Zhou C
      – PersonEntity:
          Name:
            NameFull: Szoke A
      – PersonEntity:
          Name:
            NameFull: Neumayr L
      – PersonEntity:
          Name:
            NameFull: Dean JP
      – PersonEntity:
          Name:
            NameFull: Ghia P
      – PersonEntity:
          Name:
            NameFull: Kipps TJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 10
              Text: 2025 Oct 30
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1528-0020
          Numbering:
            – Type: volume
              Value: 146
            – Type: issue
              Value: 18
          Titles:
            – TitleFull: Blood
              Type: main
ResultId 1